Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701975 | 0.82 | L3MBTL1 (0.35) | CYP2C9 | |
| SCHEMBL7255157 | 0.79 | MTNR1A (0.36) | MTNR1AMTNR1B | |
| SCHEMBL6695838 | 0.71 | CYP2C9 (0.39) | CYP2C9DRD2 | |
| SCHEMBL6695049 | 0.70 | OPRD1 (0.36) | MTNR1AMTNR1B | |
| SCHEMBL7255081 | 0.69 | EPHX2 (0.32) | DRD2 | |
| SCHEMBL6697271 | 0.69 | POLB (0.39) | MTNR1AMTNR1BDRD2 | |
| SCHEMBL8569022 | 0.66 | NPC1 (0.55) | — | |
| SCHEMBL8569027 | 0.66 | NPC1 (0.55) | — | |
| SCHEMBL8569024 | 0.66 | NPC1 (0.55) | — | |
| SCHEMBL25173575 | 0.62 | S1PR5 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009972-A1 | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase | BRISTOL-MYERS COMPANY | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009972-A1 | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase | MT-ATP6, MT-CO1, ATP5ME | MTNR1A 304/4885MTNR1B 357/4885CYP2C9 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.